share_log

新銳醫藥：須予披露交易－合作協議及增加對目標公司的注資

NEW RAY MEDIC: DISCLOSEABLE TRANSACTION -COOPERATION AGREEMENT AND INCREASE IN CAPITALCONTRIBUTION OF THE TARGET COMPANY

Hong Kong Stock Exchange ·  May 24 21:31
Summary by Futu AI
新銳醫薬國際控股有限公司（新銳醫薬）宣布，其間接全資附屬公司浙江新銳生物藥業與夥伴A及夥伴B於2024年5月24日簽訂合作協議，旨在增加對嵊州新銳萬霖企業管理有限公司（目標公司）的注資，以及參與營運和管理。目標公司成立於2024年3月18日，初步註冊資本為人民幣1百萬元，並將增加至人民幣34百萬元。浙江新銳生物藥業將注資約人民幣13.26百萬元，由集團內部資源支付。該投資將被視為按公平值計入損益的金融資產，不會綜合入賬於新銳醫薬的財務業績。目標公司將參與發展位於中國浙江省嵊州的健康食品產業園項目，包括收購土地使用權及發展相關設施。此次合作協議根據上市規則第14章規定，構成須予披露交易。
新銳醫薬國際控股有限公司（新銳醫薬）宣布，其間接全資附屬公司浙江新銳生物藥業與夥伴A及夥伴B於2024年5月24日簽訂合作協議，旨在增加對嵊州新銳萬霖企業管理有限公司（目標公司）的注資，以及參與營運和管理。目標公司成立於2024年3月18日，初步註冊資本為人民幣1百萬元，並將增加至人民幣34百萬元。浙江新銳生物藥業將注資約人民幣13.26百萬元，由集團內部資源支付。該投資將被視為按公平值計入損益的金融資產，不會綜合入賬於新銳醫薬的財務業績。目標公司將參與發展位於中國浙江省嵊州的健康食品產業園項目，包括收購土地使用權及發展相關設施。此次合作協議根據上市規則第14章規定，構成須予披露交易。
XINYUI MEDICAL PHARMACEUTICALS INTERNATIONAL HOLDINGS LIMITED (XINYUI PHARMACEUTICALS) ANNOUNCED THAT ITS INDIRECT WHOLLY OWNED SUBSIDIARIES ZHEJIANG XINRUI BIOPHARMACEUTICALS PARTNERS A AND PARTNER B SIGNED A COOPERATION AGREEMENT ON MAY 24, 2024 TO INCREASE INVESTMENT IN SHENGZHOU XINYUANLIN ENTERPRISE MANAGEMENT CO., LTD. (TARGET COMPANY) AND PARTICIPATE IN OPERATIONS and management. The target company was established on 18 March 2024 with an initial registered capital of RMB 1 million and will increase to RMB34 million. Zhejiang New Biopharmaceuticals will invest approximately RMB13.26 million, paid for by the Group's internal resources. The investment will be treated as a financial asset at fair value and will not be integrated into the financial results of Novicea Pharmaceuticals. The target company will participate in the development of a health food industrial park in Shengzhou, Zhejiang Province, China, including the acquisition of land use rights and development related facilities. This cooperation agreement constitutes a disclosable transaction pursuant to Chapter 14 of the Listing Rules.
XINYUI MEDICAL PHARMACEUTICALS INTERNATIONAL HOLDINGS LIMITED (XINYUI PHARMACEUTICALS) ANNOUNCED THAT ITS INDIRECT WHOLLY OWNED SUBSIDIARIES ZHEJIANG XINRUI BIOPHARMACEUTICALS PARTNERS A AND PARTNER B SIGNED A COOPERATION AGREEMENT ON MAY 24, 2024 TO INCREASE INVESTMENT IN SHENGZHOU XINYUANLIN ENTERPRISE MANAGEMENT CO., LTD. (TARGET COMPANY) AND PARTICIPATE IN OPERATIONS and management. The target company was established on 18 March 2024 with an initial registered capital of RMB 1 million and will increase to RMB34 million. Zhejiang New Biopharmaceuticals will invest approximately RMB13.26 million, paid for by the Group's internal resources. The investment will be treated as a financial asset at fair value and will not be integrated into the financial results of Novicea Pharmaceuticals. The target company will participate in the development of a health food industrial park in Shengzhou, Zhejiang Province, China, including the acquisition of land use rights and development related facilities. This cooperation agreement constitutes a disclosable transaction pursuant to Chapter 14 of the Listing Rules.
Helpful
Not Helpful

This announcement is a separate document:

Doc 1     View Translation

The translation is provided by third-party software.


The information provided by Futu AI is automatically generated by third-party artificial intelligence (AI) software based on news content. It is only available to users located outside of China mainland.


The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.